Oppenheimer raised the firm’s price target on Amgen (AMGN) to $400 from $380 and keeps an Outperform rating on the shares ahead of quarterly results. The firm estimates Q4 total revenue of $9.26B vs. $9.47B consensus, and adjusted EPS of $4.64 vs. $4.73 consensus. Oppenheimer’s longer-term revenue outlook is generally in line with consensus estimates, increasing from $36.1B vs. $36.4B consensus in 2025 to $41.8B vs. $41.7B consensus in 2030.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen Advances Teprotumumab Program With Completed Phase 1 Study in Healthy Chinese Volunteers
- Amgen price target raised to $390 from $380 at UBS
- Amgen downgraded to Market Perform from Outperform at Bernstein
- Amgen Expands Sleep Apnea Pipeline With Phase 3 Trial of Maridebart Cafraglutide
- Amgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next